| 摘要 |
<p>The present invention relates to pharmaceutical compositions for sustained release of HMG-CoA reductase inhibitors, in particular fluvastatin. The said compositions are useful for the treatment of hypercholesterolemia, and have the further advantages of (i) decreasing the incidence of undesirable gastro-intestinal side-effects, and (ii) avoiding undesirable increases of serum transaminase levels. Furthermore, undesirable up-regulation of HMG-CoA reductase levels is significantly reduced by administration of the said sustained release compositions.</p> |
